IMGN-853

Christopher Marai of Oppenheimer on Thursday upgraded shares of ImmunoGen, Inc. (NASDAQ: IMGN) to Outperform from Perform with an $11 price target as recent weakness in shares following disappointing results from MARIANNE creates a buying opportunity given a "catalyst-rich" next 12 months. "We view...